Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
43 hedge funds and large institutions have $8.09M invested in Clearside Biomedical in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.07% less ownership
Funds ownership: 0.83% → 0.76% (-0.07%)
10% less capital invested
Capital invested by funds: $8.97M → $8.09M (-$879K)
45% less call options, than puts
Call options by funds: $44K | Put options by funds: $80K
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$193K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$27K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$17.6K |
| 4 |
ARC
Advisor Resource Council
Dallas,
Texas
|
+$14.4K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$407K |
| 2 |
Renaissance Technologies
New York
|
-$160K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$79.5K |
| 4 |
BlackRock
New York
|
-$73.4K |
| 5 |
First Manhattan
New York
|
-$60.3K |
CLSD Hedge Fund Activity: Q1 2025 in Review
43 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2025, worth a combined $8.09M — down 9.8% from $8.97M a quarter earlier.
Fund positioning in CLSD was balanced in Q1 2025: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 15 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $193K. The largest seller was Carmignac Gestion, cutting an estimated $407K.
- 43 institutional investors held Clearside Biomedical (CLSD) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $8.09M of Clearside Biomedical stock for Q1 2025, down 9.8% quarter-over-quarter.
- 4 funds opened new Clearside Biomedical positions in Q1 2025 and 4 closed out, a net change of 0 holders.
- The largest Clearside Biomedical buyer in Q1 2025 was GSA Capital Partners, an estimated $193K added.
- The largest Clearside Biomedical seller in Q1 2025 was Carmignac Gestion, an estimated $407K sold.
Based on aggregated 13F filings for Q1 2025.